See more : Public Joint Stock Company RBC (RBCM.ME) Income Statement Analysis – Financial Results
Complete financial analysis of Zealand Pharma A/S (ZLDPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zealand Pharma A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aier Eye Hospital Group Co., Ltd. (300015.SZ) Income Statement Analysis – Financial Results
- Ruentex Development Co.,Ltd. (9945.TW) Income Statement Analysis – Financial Results
- Nykredit Invest Danske Aktier Akk KL (NYIDAA.CO) Income Statement Analysis – Financial Results
- China Communications Services Corporation Limited (CUCSF) Income Statement Analysis – Financial Results
- Intermap Technologies Corporation (ITMSF) Income Statement Analysis – Financial Results
Zealand Pharma A/S (ZLDPF)
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 342.79M | 103.99M | 292.57M | 353.31M | 41.33M | 37.98M | 139.78M | 234.78M | 187.68M | 153.77M | 6.57M | 223.57M | 142.28M | 87.36M | 25.32M | 56.26M | 59.92M |
| Cost of Revenue | 19.17M | 30.71M | 118.81M | 90.57M | 415.00K | 180.24M | 14.63M | 31.46M | 22.27M | 13.78M | 872.00K | 15.93M | 112.00K | 11.20M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 323.61M | 73.28M | 173.75M | 262.75M | 40.92M | -142.26M | 125.15M | 203.32M | 165.41M | 140.00M | 5.70M | 207.63M | 142.17M | 76.15M | 25.32M | 56.26M | 59.92M |
| Gross Profit Ratio | 94.41% | 70.47% | 59.39% | 74.37% | 99.00% | -374.60% | 89.53% | 86.60% | 88.14% | 91.04% | 86.74% | 92.87% | 99.92% | 87.18% | 100.00% | 100.00% | 100.00% |
| Research & Development | 684.90M | 614.04M | 588.45M | 604.08M | 561.42M | 438.22M | 324.67M | 268.16M | 214.96M | 180.04M | 164.47M | 182.76M | 126.94M | 151.28M | 93.09M | 85.76M | 105.14M |
| General & Administrative | 73.80M | 274.24M | 260.99M | 202.77M | 67.88M | 78.00M | 47.47M | 52.50M | 44.61M | 39.83M | 34.16M | 27.61M | 34.91M | 39.73M | 16.12M | 15.31M | 17.54M |
| Selling & Marketing | 16.05M | 32.30M | 375.27M | 285.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 89.85M | 306.54M | 636.26M | 488.03M | 67.88M | 78.00M | 47.47M | 52.50M | 44.61M | 39.83M | 34.16M | 27.61M | 34.91M | 39.73M | 16.12M | 15.31M | 17.54M |
| Other Expenses | 121.10M | 0.00 | -759.00K | -602.00K | -444.00K | 1.10B | 0.00 | 777.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 895.85M | 920.59M | 1.22B | 1.09B | 628.86M | 515.59M | 371.53M | 318.97M | 246.74M | 213.53M | 191.32M | 175.24M | 133.41M | 196.05M | 105.24M | 100.95M | 122.45M |
| Cost & Expenses | 915.03M | 920.59M | 1.34B | 1.18B | 629.28M | 695.82M | 386.16M | 350.42M | 269.00M | 227.31M | 192.19M | 191.17M | 133.52M | 196.05M | 105.24M | 100.95M | 122.45M |
| Interest Income | 45.32M | 6.54M | 44.00K | 895.00K | 5.41M | 4.26M | 2.05M | 592.00K | 139.00K | 719.00K | 3.04M | 5.63M | 6.56M | 4.13M | 4.32M | 11.21M | 0.00 |
| Interest Expense | 24.89M | 56.46M | 4.09M | 2.90M | 3.21M | 15.08M | 18.91M | 32.16M | 32.71M | 2.02M | 81.00K | 186.00K | 1.95M | 63.00K | 104.00K | 257.00K | 0.00 |
| Depreciation & Amortization | 25.09M | 30.71M | 25.12M | 42.69M | 13.54M | 4.51M | 4.76M | 5.41M | 6.22M | 5.93M | 5.91M | 5.32M | 4.13M | 4.13M | 3.69M | 3.28M | 0.00 |
| EBITDA | -658.89M | -665.26M | -711.85M | -627.94M | -562.64M | -442.00M | -246.28M | -118.27M | -81.25M | -64.54M | -177.68M | 41.92M | 14.68M | -104.57M | -76.25M | -44.69M | -62.53M |
| EBITDA Ratio | -192.22% | -639.76% | -332.94% | -246.80% | -1,361.23% | -1,761.72% | -176.19% | -50.37% | -45.11% | -43.50% | -2,687.30% | 19.39% | 13.67% | -119.71% | -284.06% | -79.43% | -104.35% |
| Operating Income | -572.24M | -816.60M | -1.05B | -828.76M | -587.94M | 652.39M | -246.38M | -115.65M | -81.33M | -73.54M | -185.62M | 32.40M | 8.76M | -108.70M | -79.93M | -44.69M | -62.53M |
| Operating Income Ratio | -166.94% | -785.30% | -358.96% | -234.57% | -1,422.45% | 1,717.86% | -176.27% | -49.26% | -43.33% | -47.82% | -2,823.52% | 14.49% | 6.16% | -124.43% | -315.67% | -79.43% | -104.35% |
| Total Other Income/Expenses | -136.63M | -134.89M | 25.43M | -47.29M | 11.27M | -27.33M | -31.39M | -43.76M | -38.51M | 1.05M | 1.94M | 3.98M | 4.61M | 4.06M | 4.86M | 10.96M | 7.53M |
| Income Before Tax | -708.87M | -972.04M | -1.03B | -839.65M | -576.68M | 625.06M | -277.77M | -159.41M | -119.83M | -72.49M | -183.68M | 36.37M | 13.38M | -104.63M | -75.71M | -33.73M | -55.00M |
| Income Before Tax Ratio | -206.79% | -934.78% | -351.01% | -237.65% | -1,395.20% | 1,645.88% | -198.73% | -67.90% | -63.85% | -47.14% | -2,793.98% | 16.27% | 9.40% | -119.78% | -299.02% | -59.96% | -91.79% |
| Income Tax Expense | -5.13M | -6.43M | -8.79M | 7.08M | -5.14M | 43.77M | -5.50M | -5.50M | -5.88M | -7.50M | 81.00K | 186.00K | 6.56M | 0.00 | 4.32M | -3.28M | 0.00 |
| Net Income | -703.74M | -965.61M | -1.02B | -846.73M | -571.54M | 581.28M | -272.27M | -153.91M | -113.96M | -64.99M | -183.68M | 36.37M | 13.38M | -104.63M | -75.71M | -33.73M | -55.00M |
| Net Income Ratio | -205.30% | -928.60% | -348.01% | -239.65% | -1,382.77% | 1,530.61% | -194.79% | -65.56% | -60.72% | -42.26% | -2,793.98% | 16.27% | 9.40% | -119.78% | -299.02% | -59.96% | -91.79% |
| EPS | -12.44 | -20.90 | -23.75 | -22.07 | -16.91 | 18.94 | -9.77 | -6.33 | -4.94 | -2.87 | -8.12 | 1.61 | 0.60 | -5.75 | -4.28 | -1.91 | -3.11 |
| EPS Diluted | -12.44 | -20.90 | -23.75 | -22.07 | -16.91 | 18.94 | -9.77 | -6.33 | -4.94 | -2.87 | -8.12 | 1.60 | 0.60 | -5.75 | -4.28 | -1.91 | -3.11 |
| Weighted Avg Shares Out | 56.59M | 46.20M | 42.87M | 38.37M | 33.80M | 30.69M | 27.85M | 24.31M | 23.05M | 22.63M | 22.63M | 22.63M | 22.33M | 18.20M | 17.68M | 17.68M | 17.68M |
| Weighted Avg Shares Out (Dil) | 56.59M | 46.20M | 42.87M | 38.37M | 33.80M | 30.70M | 27.85M | 24.31M | 23.05M | 22.63M | 22.63M | 22.73M | 22.33M | 18.20M | 17.68M | 17.68M | 17.68M |
Zealand Pharma: Survodutide Has Potential Beyond Obesity Treatment
Positive results achieved in phase 2 study using survodutide for the treatment of patients with MASH; Primary endpoint of histological improvement of MASH met with statistical significance. The global non-alcoholic steatohepatitis [NASH] market size is expected to grow to $14.53...
Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.
Novo Nordisk's $600 billion valuation makes it one of the top healthcare companies in the world. For investors looking for stocks with more upside, upstart Zealand Pharma may fit the bill.
Zealand Pharma A/S (ZEAL) Q4 2023 Earnings Call Transcript
Zealand Pharma A/S (ZEAL) Q4 2023 Earnings Call Transcript
Zealand Pharma convenes its Annual General Meeting 2024
Company Announcement – No. 10 / 2024 Zealand Pharma convenes its Annual General Meeting 2024 Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no.
Zealand Pharma shares surge on liver disease drug trial data
Zealand Pharma shares jumped 20% after an experimental obesity treatment it is developing with Boehringer Ingelheim yielded "groundbreaking" Phase II trial results in the treatment of fatty liver.
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
Zealand Pharma A/S (ZEAL) Q3 2023 Earnings Call Transcript
Zealand Pharma A/S (ZEAL) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Anna Krassowska - Vice President-Investor Relations Adam Steensberg - President & Chief Executive Officer David Kendall - Chief Medical Officer Henriette Wennicke -...
Factbox: Weight-loss drugs: the next gold rush
Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.
Zealand Pharma A/S (ZLDPF) is on the Move, Here's Why the Trend Could be Sustainable
Zealand Pharma A/S (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in Zealand Pharma A/S (ZLDPF) is Your Friend, Here's Why
Zealand Pharma A/S (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Source: https://incomestatements.info
Category: Stock Reports
What are the future financial projections for Zealand Pharma?
Zealand Pharma AS (OCSE:ZEAL) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $54.77 million, and the earnings are expected to come in at -$4.06 per share.
What is Zealand Pharma’s revenue for 2024?
Revenue estimates for Zealand Pharma AS (OCSE:ZEAL) have declined from $190.56 million to $163.57 million for the full year 2024 and from $0.83 billion to $0.73 billion for 2025 over the past 90 days.